SCHEDULE: S.H.N. Financial Boosts Plus Therapeutics Stake

S.H.N. Financial Investments Ltd. has increased its beneficial ownership in Plus Therapeutics, Inc. to 1.51% of common stock.

Summary

• S.H.N. Financial Investments Ltd. reported beneficial ownership of 1,500,000 shares of Plus Therapeutics, Inc. common stock.
• This represents 1.51% of the company's outstanding common stock.
• The calculation is based on 99,264,526 shares outstanding as of August 8, 2025, as reported in the Issuer's Registration Statement on Form S-1.
• This filing is an amendment to a previous Schedule 13G filed on March 18, 2025, which reported 1,209,754 shares purchased on March 4, 2025.
• S.H.N. Financial Investments Ltd. holds sole voting and dispositive power over all 1,500,000 shares.

Sentiment

Score: 7

Explanation: The increased stake by an institutional investor suggests a positive view on the company's prospects, although the filing itself is purely factual and not a performance report.

Positives

• Increased stake by S.H.N. Financial Investments Ltd. from 1,209,754 shares to 1,500,000 shares indicates continued investor confidence in Plus Therapeutics, Inc.

Future Outlook

No forward-looking statements or guidance from Plus Therapeutics, Inc. are provided in this beneficial ownership filing.

Management Comments

• Nir Shamir, Chief Executive Officer of S.H.N. Financial Investments Ltd., disclaims beneficial ownership of these securities for all other purposes, to the extent he is deemed to beneficially own them.

Industry Context

This filing reflects an institutional investor's increased stake in a publicly traded company, a common activity in the financial markets. The reference to an S-1 filing suggests potential capital-raising activities by Plus Therapeutics, which is typical for growth-oriented companies, particularly in sectors requiring significant R&D investment.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership and does not contain information for direct comparison of operational results or financial performance against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The increased institutional ownership could be viewed positively, potentially signaling confidence in the company. The reference to an S-1 filing might imply potential dilution if it's for a new share offering.

Key Dates

Recommendation

The filing indicates an increased stake by an institutional investor, S.H.N. Financial Investments Ltd., which can be interpreted as a vote of confidence. However, the reference to the Issuer's Registration Statement on Form S-1 filed on August 12, 2025, suggests a potential capital raise, which could lead to share dilution. Without further details on the company's financial performance or the specifics of the S-1 filing, a 'hold' recommendation is prudent, acknowledging both the positive investor interest and potential dilutive events.

Keywords

Plus Therapeutics, S.H.N. Financial Investments, Beneficial Ownership, Schedule 13G, Common Stock, Investment